Rheacell Study
Clinical trial for the treatment of leg ulcers (Open Leg)
People suffering from leg ulcers are often restricted in their quality of life – this is due to pain, a complicated healing process and the unsightly appearance of the disease. Satisfactory treatment is not always possible and there are only a few treatment options available.
In this clinical trial, we are investigating a new treatment approach with a so-far unapproved drug that could potentially be a good alternative for patients with leg ulcers.
You may be eligible if:
- You are at least 18 years old
- You have been diagnosed with chronic leg ulcers (open leg) due to venous insufficiency
- You are available for 17 appointments at a study centre over approximately 16-month study period
The aim of this study is to investigate the efficacy and safety of a new, unapproved drug. For comparison purposes, the participants will be randomly divided into two groups. While one group receives the drug to be tested, the other group receives a placebo.
Advantages of participating in the study:
- Regular medical examinations and intensive support
- You support medical research and help other patients
- All study-related measures (investigational drug, laboratory tests, etc) are paid for by the sponsor of the study – you do not incur any costs
If you are interested in participating in this study, please contact us. We will contact you promptly to discuss whether participation is possible and beneficial for you.
What can I do if I’m interested in taking part? If you would like further information about the study, please contact the study team:
01202 339050
Recruitment – Open to recruitment
Lead Research staff contact for this study
Wendy Higson
Sarah Orr
Brenda Furlong
Principle Investigator for this study
Dr Patrick Moore
Response Study
What can I do if I’m interested in taking part? If you would like further information about the study, please contact the study team:
01202 339050
Recruitment – Open to recruitment
Lead Research staff contact for this study
Tracey Dare
Sarah Orr
Rebecca Cutts
Wendy Higson
Principle Investigator for this study
Dr Patrick Moore
COAT Study
This study is funded by the National Institute for Health Research. This is the main government funder for health studies in the NHS. The study is being sponsored by the University of Southampton and is being coordinated by the Southampton Clinical Trials Unit. Patients from The Adam Practice can take part, though there is no obligation to do so. Participation is entirely voluntary.
The study aims to compare a 5 day versus a 7 day course of an antibiotic called Flucloxacillin in patients with a diagnosis of cellulitis.
Cellulitis is a deep skin infection. Most people with cellulitis in the U.K. are treated with the antibiotic flucloxacillin for 7 days. However, research studies show that short courses of antibiotics (5 days or less) work as well as longer courses for many different types of infections, including serious infections like pneumonia. For cellulitis, there have been some studies that have shown that short courses work as well as longer course, and U.K. guidance recommends a 5 – 7 day course. However, there have not been any studies comparing short and longer courses of flucloxacillin prescribed outside of hospital settings (i.e. GP surgeries). Taking longer courses of antibiotics is likely to cause more side effects and kill off the ‘good bacteria’ that help keep us healthy.
Patients >18 years who have a diagnosis of cellulitis of one leg may be eligible to take part. Patients who have a penicillin allergy will not be suitable for the study.
Please link to the COAT study information site for full information.
Recruitment – Open to recruitment
Lead Research staff contact for this study
Rebecca Cutts
Wendy Higson
Tracey Dare
Helen Smith
Sally Bradfield
Sarah Orr
Brenda Furlong
Principle Investigator for this study
Dr Patrick Moore
ATHENA Study
ATHENA (Amitriptyline for the prevention of post-herpetic neuralgia) is a trial involving adults who are 50 years or older and have just been diagnosed with shingles. The study is funded by NIHR Health Technology Assessment and being led by a team at Bristol University.
Shingles can cause nerve pain in the area of the shingles rash, months after the rash has gone. This is called “post-herpetic neuralgia”. Currently there are no treatments to prevent this, but it is thought that a drug called amitriptyline may help and this trial will help to determine if this is the case.
Eligible participants will be asked to take tablets for 10 weeks and will be followed up for a 12-month period. They will be asked to complete seven questionnaires, each 5-10 minutes long. As this is a clinical trial the participants will not know whether they are taking the trial medication or a placebo “dummy tablet”.
Further information can be found by following the link below. If you have just been diagnosed with shingles and are interested in the trial, please inform your GP and/ or contact the research team.
Recruitment – Open to recruitment
Lead research staff contact for this study
Sally Bradfield
Wendy Higson,
Rebecca Cutts
Tracey Dare
Principal Investigator
Dr Sarah Lumley
Sub Investigators
Dr Ben Oxley
Dr Patrick Moore
Dr Charlie Powell
| Additional Information – https://athena-study.bristol.ac.uk/about-the-study/ If you would like to know more please contact us by telephone or e mail: Research Team Voicemail 01202 339050 [email protected] . |